Ignite Creation Date:
2025-12-25 @ 12:59 AM
Ignite Modification Date:
2025-12-25 @ 11:13 PM
Study NCT ID:
NCT05244993
Status:
UNKNOWN
Last Update Posted:
2022-07-12
First Post:
2022-02-08
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer
Sponsor:
Liaoning Cancer Hospital & Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-07
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-03
Completion Date Type:
ESTIMATED
First Submit Date:
2022-02-08
First Submit QC Date:
None
Study First Post Date:
2022-02-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-07-11
Last Update Post Date:
2022-07-12
Last Update Post Date Type:
ACTUAL